MedTrace Logo

SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults

NCT00238784 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1300

Last updated 2008-01-14

No results posted yet for this study

Summary

The purpose of this study is to compare Symbicort Single Inhaler treatment with the Best Conventional Practice in patients with persistent asthma

Conditions

Interventions

DRUG

Budesonide/formoterol Turbuhaler

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Rita Medical Science Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2005-10-31
Completion
2005-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00238784 on ClinicalTrials.gov